Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy InMed Pharmaceuticals stock | $2.95

Learn how to easily invest in InMed Pharmaceuticals stock.

InMed Pharmaceuticals Inc is a biotechnology business based in the US. InMed Pharmaceuticals shares (INM) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in InMed Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

InMed Pharmaceuticals stock price (NASDAQ: INM)

Use our graph to track the performance of INM stocks over time.

InMed Pharmaceuticals shares at a glance

Information last updated 2021-07-28.
Latest market close$2.95
52-week range$2.38 - $5.66
50-day moving average $2.83
200-day moving average $3.55
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy InMed Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy InMed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InMed Pharmaceuticals price performance over time

Historical closes compared with the close of $2.95 from 2021-05-28

1 week (2021-07-25) N/A
1 month (2021-07-02) -7.52%
3 months (2021-05-05) -17.60%
6 months (2021-02-01) N/A
1 year (2020-08-01) N/A
2 years (2019-08-01) N/A
3 years (2018-08-01) N/A
5 years (2016-08-01) N/A

InMed Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -52.16%
Return on equity TTM -105.12%
Profit margin 0%
Book value $1.29
Market capitalisation $24.1 million

TTM: trailing 12 months

Shorting InMed Pharmaceuticals shares

There are currently 93,348 InMed Pharmaceuticals shares held short by investors – that's known as InMed Pharmaceuticals's "short interest". This figure is 397.4% up from 18,766 last month.

There are a few different ways that this level of interest in shorting InMed Pharmaceuticals shares can be evaluated.

InMed Pharmaceuticals's "short interest ratio" (SIR)

InMed Pharmaceuticals's "short interest ratio" (SIR) is the quantity of InMed Pharmaceuticals shares currently shorted divided by the average quantity of InMed Pharmaceuticals shares traded daily (recently around 93348). InMed Pharmaceuticals's SIR currently stands at 1. In other words for every 100,000 InMed Pharmaceuticals shares traded daily on the market, roughly 1000 shares are currently held short.

To gain some more context, you can compare InMed Pharmaceuticals's short interest ratio against those of similar companies.

However InMed Pharmaceuticals's short interest can also be evaluated against the total number of InMed Pharmaceuticals shares, or, against the total number of tradable InMed Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case InMed Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 InMed Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0117% of the tradable shares (for every 100,000 tradable InMed Pharmaceuticals shares, roughly 12 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against InMed Pharmaceuticals.

Find out more about how you can short InMed Pharmaceuticals stock.

InMed Pharmaceuticals share dividends

We're not expecting InMed Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Have InMed Pharmaceuticals's shares ever split?

InMed Pharmaceuticals's shares were split on a 1:33 basis on 5 July 2020. So if you had owned 33 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InMed Pharmaceuticals shares – just the quantity. However, indirectly, the new 3200% higher share price could have impacted the market appetite for InMed Pharmaceuticals shares which in turn could have impacted InMed Pharmaceuticals's share price.

InMed Pharmaceuticals share price volatility

Over the last 12 months, InMed Pharmaceuticals's shares have ranged in value from as little as $2.38 up to $5.661. A popular way to gauge a stock's volatility is its "beta".

INM.US volatility(beta: 1.43)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InMed Pharmaceuticals's is 1.4309. This would suggest that InMed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put InMed Pharmaceuticals's beta into context you can compare it against those of similar companies.

InMed Pharmaceuticals overview

InMed Pharmaceuticals Inc. , a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc.

InMed Pharmaceuticals in the news

There are no recent company news

Frequently asked questions

What percentage of InMed Pharmaceuticals is owned by insiders or institutions?
Currently 0.861% of InMed Pharmaceuticals shares are held by insiders and 6.337% by institutions.
When does the fiscal year end for InMed Pharmaceuticals?
InMed Pharmaceuticals's fiscal year ends in June.
Where is InMed Pharmaceuticals based?
InMed Pharmaceuticals's address is: 815 West Hastings Street, Vancouver, BC, Canada, V6C 1B4

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site